Associate Professor, Medicine, Case Western Reserve University School of Medicine
Hematology
Dr. Mikkael A. Sekeres, MD
|
|
Give Review
Mikkael Sekeres is an expert in the field of Hematology. He researched medicine at Perelman School of Medicine at the University of Pennsylvania. He received awards:"Regional Top Doctor" and "CMS Meaningful Use Stage 1 Certification". Mikkael A. Sekeres, MD is also a published physician. He has 102 publication published. The most recent publication is: Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled,... He accepts all Medicare patients.
Publications
- Outcomes of patients with Myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.
- Genomic patterns associated with hypoplastic compared to hyperplastic Myelodysplastic syndromes.
- Comparing the prognostic value of risk stratifying models for patients with lower-risk Myelodysplastic syndromes: Is one model better?
- Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in Myeloid neoplasms.
- Reducing Time to Antibiotic Administration for Febrile Neutropenia in the Emergency Department.
- Genetic and molecular characterization of myelodysplastic syndromes and related Myeloid neoplasms.
- Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Lingering Uncertainties and Emerging Possibilities.
- Racial differences in allogeneic hematopoietic Cell transplantation outcomes among African Americans and whites.
- More is better: combination therapies for Myelodysplastic syndromes.
- Impact of vancomycin-resistant enterococcal bacteremia on outcome during Acute myeloid leukemia induction therapy.
- The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine.
- Is the cure the poison? The evolving story of therapy-related Myeloid malignancies.
- Outcome of patients with low-risk and intermediate-1-risk Myelodysplastic syndrome after hypomethylating agent failure: A Report on Behalf of the MDS Clinical Research...
- Screening for SF3B1 mutations is a useful tool to differentiate between acquired clonal and non-clonal sideroblastic Anemia.
- Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk Myelodysplastic syndromes.
- SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed Acute myeloid leukaemia.
- Genetic alterations of the cohesin complex genes in Myeloid malignancies.
- A phase II multicenter rabbit anti-thymocyte globulin trial in patients with Myelodysplastic syndromes identifying a novel model for response prediction.
- Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.
- Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patien...
- PDGFRB-rearranged T-lymphoblastic Leukemia/lymphoma occurring with myeloid neoplasms: The missing link supporting a stem cell origin.
- Distinct iron architecture in SF3B1 mutant Myelodysplastic syndromes patients is linked to an SLC25A37 splice variant with a retained intron.
- Clinicopathologic and molecular characterization of Myeloid neoplasms harboring isochromosome 17(q10).
- Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodys...
- Initial transfusion frequency and survival in Myelodysplastic syndromes: hopping onto a fast train to nowhere.
- Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine.
- Recurrent genetic defects on chromosome 7q in Myeloid neoplasms.
- Neoadjuvant Pertuzumab in Early HER2-Positive Breast Cancer.
- Making sense of the Myelodysplastic/myeloproliferative neoplasms overlap syndromes.
- How we treat higher-risk Myelodysplastic syndromes.
- Extended survival and reduced risk of AML progression in erythroid responsive lenalidomide-treated patients with lower-risk del(5q) MDS.
- A Drug's Life: The Pathway to Drug Approval.
- Predictive Factors for Latency Period and a Prognostic Model for Survival in Patients with Therapy-related AML.
- Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML.
- Epidemiology and risk factors for infections in Myelodysplastic syndromes.
- Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in Myeloid malignancies.
- Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related Neoplasms.
- Somatic SETBP1 mutations in Myeloid malignancies.
- Patterns of missplicing due to somatic U2AF1 mutations in Myeloid neoplasms.
- Febrile Neutropenia in Hematologic Malignancies.
- Outcomes in obese and overweight Acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight.
- Bone Marrow Transplantation (BMT) in Myelodysplastic Syndromes: To BMT or Not to BMT--That Is the Question.
- Randomized, dose-escalation study of the p38? MAPK inhibitor SCIO-469 in patients with Myelodysplastic syndrome.
- Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in Myeloid malignancies.
- The need for additional genetic markers for Myelodysplastic syndrome stratification: what does the future hold for prognostication?
- Defining Incidence, Risk Factors, and Impact on Survival of Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myelo...
- Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in Myelodysplastic syndrome with chromosome 5q deletion.
- Improving the diagnosis and treatment of patients with Myelodysplastic syndromes through a performance improvement initiative.
- Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated Acute myeloid leukemia.
- Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic Leukemia but largely absent in juvenile myelomonocytic leu...
- Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk Myelodysplastic syndromes.
- The race for survival in Myelodysplastic syndromes.
- Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in Acute myeloid leukemia.
- SF3B1 haploinsufficiency leads to formation of ring sideroblasts in Myelodysplastic syndromes.
- Development of a modified surveillance definition of central line-associated bloodstream infections for patients with hematologic Malignancies.
- Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis.
- Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed Acute lymphoblastic leukemia.
- Combination strategies in Myelodysplastic syndromes.
- A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap Myelodysplastic/myeloprolif...
- De Novo polycythaemia vera arising 5???years following Acute myeloid leukemia remission: suggestion of a chemotherapy resistant JAK2 clone.
- My AML Cytogenetics Classification Scheme Is Better Than Yours.
- Blood consult: treating del(5q) Myelodysplastic syndromes.
- The Baby Whisperer.
- The avastin story.
- Lenalidomide in MDS: 4th time's a charm.
- Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic Leukemia.
- A piece of my mind. The road warriors.
- Mutational spectrum analysis of chronic myelomonocytic Leukemia includes genes associated with epigenetic regulation: UTX, EZH2 and DNMT3A.
- Lenalidomide in del 5q MDS: Responses and side effects revisited.
- Management of lower-risk Myelodysplastic syndromes:the art and evidence.
- Efficacy of rabbit anti-thymocyte globulin in severe aplastic Anemia.
- A phase 2 study of lenalidomide monotherapy in patients with deletion 5q Acute myeloid leukemia: Southwest Oncology Group Study S0605.
- Tricking or treating Myelodysplastic syndromes.
- SNP array-based karyotyping: differences and similarities between aplastic Anemia and hypocellular myelodysplastic syndromes.
- Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related Myeloid malignancies.
- Perceptions of Disease State, Treatment Outcomes, and Prognosis Among Patients with Myelodysplastic Syndromes: Results From an Internet-Based Survey.
- A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary Acute myeloid leukemia.
- Subcutaneous or intravenous administration of romiplostim in Thrombocytopenic patients with lower risk myelodysplastic syndromes.
- If Nostradamus were treated for MDS.
- Epidemiology, natural history, and practice patterns of patients with Myelodysplastic syndromes in 2010.
- Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk Myelodysplastic syndromes.
- A hallmark moment.
- A Phase II trial of gemcitabine and mitoxantrone for patients with Acute myeloid leukemia in first relapse.
- Impact of weekend admissions on quality of care and outcomes in patients with Acute myeloid leukemia.
- How flipping burgers can cure Leukemia.
- Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk Myelodysplastic syndromes.
- The epidemiology of Myelodysplastic syndromes.
- Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of Acute promyelocytic leukemia.
- Safety and efficacy of romiplostim in patients with lower-risk Myelodysplastic syndrome and thrombocytopenia.
- Myelodysplastic syndromes: a practical approach to diagnosis and treatment.
- Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in Myeloid malignancies.
- New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in Acute myeloid leukemia.
- What my patients taught me about love.
- Defining prior therapy in Myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment.
- REVelation (del: 5q).
- Time from diagnosis to treatment initiation predicts survival in younger, but not older, Acute myeloid leukemia patients.
- Treatment of MDS: something old, something new, something borrowed...
- Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk Myelodysplastic syndromes.
- 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl,...
- Characteristics of US patients with Myelodysplastic syndromes: results of six cross-sectional physician surveys.
- Rigosertib versus best supportive care for patients with high-risk Myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled,...
Schools
University Of Pennsylvania School Of Medicine
Brigham and Women39s Hospital
Dana Farber Cancer Institute
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Bladder Cancer
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
Education
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Perelman School of Medicine at the University of Pennsylvania
Hospital
-
Cleveland Clinic
Drug Facts
| NPI NUMBER | 1497710941 | |
| NPPES Provider LastName | SEKERES | |
| NPPES Provider FirstName | MIKKAEL | |
| NPPES Provider ZIPCode | 441950001 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 300.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1497710941 |
| Last Name Of The Provider | SEKERES |
| First Name Of The Provider | MIKKAEL |
| View All |
Similar Doctors
|
|
Dr. Alok A. Khorana, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dragana Tomic, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer R. Eads, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Linda M. Sandhaus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel Babu, MD |
|
|
Sudipto Mukherjee |